Dr. Yusuf Menda, MD
Claim this profileThe University of Iowa Theranostics Center
Studies Neuroendocrine Tumors
Studies Carcinoid Tumor
9 reported clinical trials
10 drugs studied
Area of expertise
1Neuroendocrine Tumors
Stage IV
Stage III
CXCR4 positive
2Carcinoid Tumor
Stage IV
Stage III
Ki-67 positive
Affiliated Hospitals
Clinical Trials Yusuf Menda, MD is currently running
Targeted Alpha-Particle Therapy
for Neuroendocrine Tumors
This study is Phase I/IIa First-in-Human Study of \[212Pb\]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
Recruiting1 award Phase 1 & 213 criteria
FPI-2265
for Metastatic Prostate Cancer
This is an open-label, randomized, multicenter study of FPI-2265 (225Ac-PSMA-I\&T). Patient population is adult participants with PSMA positive mCRPC who have had previous treatment with with 177Lu-PSMA-617 or another 177Lu-PSMA radioconjugate (RC). The purpose of the study is to determine the safety and tolerability, and recommended dose and regiment of FPI-2265.
Recruiting1 award Phase 25 criteria
More about Yusuf Menda, MD
Clinical Trial Related3 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Yusuf Menda, MD has experience with
- 203-Lead Pentixather SPECT/CT
- 212-Lead Pentixather
- Gallium-68 Pentixafor
- [212Pb]VMT01
- [212Pb]VMT-α-NET
- FPI-2265 (225Ac-PSMA-I&T)
Breakdown of trials Yusuf Menda, MD has run
Neuroendocrine Tumors
Carcinoid Tumor
Lung carcinoid
Paraganglioma
Pheochromocytoma/Paraganglioma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Yusuf Menda, MD specialize in?
Yusuf Menda, MD focuses on Neuroendocrine Tumors and Carcinoid Tumor. In particular, much of their work with Neuroendocrine Tumors has involved Stage IV patients, or patients who are Stage III.
Is Yusuf Menda, MD currently recruiting for clinical trials?
Yes, Yusuf Menda, MD is currently recruiting for 4 clinical trials in Iowa City Iowa. If you're interested in participating, you should apply.
Are there any treatments that Yusuf Menda, MD has studied deeply?
Yes, Yusuf Menda, MD has studied treatments such as 203-Lead Pentixather SPECT/CT, 212-Lead Pentixather, Gallium-68 Pentixafor.
What is the best way to schedule an appointment with Yusuf Menda, MD?
Apply for one of the trials that Yusuf Menda, MD is conducting.
What is the office address of Yusuf Menda, MD?
The office of Yusuf Menda, MD is located at: The University of Iowa Theranostics Center, Iowa City, Iowa 52242 United States. This is the address for their practice at the The University of Iowa Theranostics Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.